Ifetroban | BMS-180291 | TxA2/PGH2 Receptor Antagonist | AmBeed-信号通路专用抑制剂

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

✕

大规格询价

* 公司或机构名称：

* 姓名：

* 电话：

* 邮箱： * 国家/区域： * 需求量：

* 货号：

* CAS号：

* 产品名称：在线留言：

✕

摩尔计算器

计算溶液所需的质量，体积或浓度。 Ambeed 摩尔浓度计算器基于以下方程式：

浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)=质量 (g)

浓度

x

体积

x

分子量

=

质量

*在制备母液时，请始终参考产品标签或 MSDS / COA（在产品页面可下载）上所显示的对应批次产品的分子量。

✕

靶点

靶点	数值

✕

总药量计算器

动物实验：给药剂量 mg/kg 动物体重 g 动物数量只每天给药次给药天

需要的总药量： mg

✕

工作液计算器

动物实验：给药剂量 mg/kg 动物体重 g 给药体积 μL

您需要配制的工作液浓度为：mg/mL

✕

细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源

✕

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02216357	-		Completed	-	-
NCT03340675	Duchenne Muscular Dystrophy Ca... 展开 >>rdiomyopathy Cardiomyopathy, Dilated 收起 <<	Phase 2	Not yet recruiting	December 2021	-
NCT02802228	Portal Hypertension ... 展开 >> Liver Cirrhosis 收起 <<	Phase 2	Completed	-	United States, Florida ... 展开 >> Tampa General Medical Group Tampa, Florida, United States, 33606 United States, Indiana Indiana University Indianapolis, Indiana, United States, 46202 United States, Ohio The Ohio State University Wexner Medical Center Columbus, Ohio, United States, 43210 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 United States, Texas Baylor University Medical Center Dallas, Texas, United States, 75246 United States, Virginia Virginia Commonwealth University Medical Center Richmond, Virginia, United States, 23114 收起 <<
NCT03694249	Anatomic Stage II Breast Cance... 展开 >>r Anatomic Stage IIA Breast Cancer Anatomic Stage IIB Breast Cancer Anatomic Stage III Breast Cancer Anatomic Stage IIIA Breast Cancer Anatomic Stage IIIB Breast Cancer Anatomic Stage IIIC Breast Cancer Clinical Stage II Esophageal Adenocarcinoma Clinical Stage II Esophageal Squamous Cell Carcinoma Clinical Stage II Gastric Cancer Clinical Stage II Gastroesophageal Junction Adenocarcinoma Clinical Stage IIA Esophageal Adenocarcinoma Clinical Stage IIA Gastric Cancer Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma Clinical Stage IIB Esophageal Adenocarcinoma Clinical Stage IIB Gastric Cancer Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma Clinical Stage III Esophageal Adenocarcinoma Clinical Stage III Esophageal Squamous Cell Carcinoma Clinical Stage III Gastric Cancer Clinical Stage III Gastroesophageal Junction Adenocarcinoma Distal Esophagus Squamous Cell Carcinoma Esophageal Carcinoma Estrogen Receptor Negative HER2/Neu Negative Limited Stage Small Cell Lung Carcinoma Malignant Solid Neoplasm Non-Small Cell Lung Carcinoma Pancreatic Adenocarcinoma Pathologic Stage II Esophageal Adenocarcinoma Pathologic Stage II Esophageal Squamous Cell Carcinoma Pathologic Stage II Gastric Cancer Pathologic Stage II Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIA Esophageal Adenocarcinoma Pathologic Stage IIA Esophageal Squamous Cell Carcinoma Pathologic Stage IIA Gastric Cancer Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIB Esophageal Adenocarcinoma Pathologic Stage IIB Esophageal Squamous Cell Carcinoma Pathologic Stage IIB Gastric Cancer Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma Pathologic Stage III Esophageal Adenocarcinoma Pathologic Stage III Esophageal Squamous Cell Carcinoma Pathologic Stage III Gastric Cancer Pathologic Stage III Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIIA Esophageal Adenocarcinoma Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma Pathologic Stage IIIA Gastric Cancer Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIIB Esophageal Adenocarcinoma Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma Pathologic Stage IIIB Gastric Cancer Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIIC Gastric Cancer Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma Postneoadjuvant Therapy Stage II Gastric Cancer Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma Postneoadjuvant Therapy Stage III Gastric Cancer Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma Progesterone Receptor Negative Prognostic Stage II Breast Cancer Prognostic Stage IIA Breast Cancer Prognostic Stage IIB Breast Cancer Prognostic Stage III Breast Cancer Prognostic Stage IIIA Breast Cancer Prognostic Stage IIIB Breast Cancer Prognostic Stage IIIC Breast Cancer Stage I Pancreatic Cancer Stage IA Pancreatic Cancer Stage IB Pancreatic Cancer Stage II Lung Cancer Stage II Pancreatic Cancer Stage IIA Lung Cancer Stage IIA Pancreatic Cancer Stage IIB Lung Cancer Stage IIB Pancreatic Cancer Stage III Lung Cancer Stage IIIA Lung Cancer Stage IIIB Lung Cancer Stage IIIC Lung Cancer Triple-Negative Breast Carcinoma 收起 <<	Phase 2	Not yet recruiting	January 2023	United States, Tennessee ... 展开 >> Vanderbilt-Ingram Cancer Center Not yet recruiting Nashville, Tennessee, United States, 37232 Contact: Vanderbilt-Ingram Service for Timely Access 800-811-8480 cip@vanderbilt.edu Principal Investigator: Ingrid Mayer, MD 收起 <<
NCT01436500	Hepatorenal Syndrome	Phase 2	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic - Arizona Phoenix, Arizona, United States, 85054 United States, California UCSD, Hillcrest Medical Center Hospital La Jolla, California, United States, 92093 UCSF (University of California-San Francisco) San Francisco, California, United States, 94143 United States, Georgia Emory University Hospital Atlanta, Georgia, United States, 30322 United States, Indiana Indiana University (Division of Gastroenterology/Hepatology) Indianapolis, Indiana, United States, 46202 United States, Michigan University of Michigan Hospital Ann Arbor, Michigan, United States, 48109 United States, New York NYU Langone Medical Center New York, New York, United States, 10016 United States, Ohio The Ohio State University Columbus, Ohio, United States, 43210 United States, Texas Baylor All Saints Medical Center Fort Worth, Texas, United States, 76104 United States, Utah University of Utah Health Sciences Center Salt Lake City, Utah, United States, 84132 United States, Virginia Virginia Commonwealth University Richmond, Virginia, United States, 23298 India MIDAS Multispeciality Hospital PVT LTD Nagpur, Maharashtra, India, 440010 收起 <<
NCT02216357	Aspirin Exacerbated Respirator... 展开 >>y Disease (AERD) 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Scripps Clinic San Diego, California, United States, 32130 United States, Kansas Kansas City Allergy and Asthma Associates, PA. Overland Park, Kansas, United States, 66210 United States, New York Allergy & Asthma Consultants of Rockland & Bergen West Nyack, New York, United States, 10994 收起 <<
NCT03326063	Nasal Polyps ... 展开 >>Asthma, Aspirin-Induced Aspirin-exacerbated Respiratory Disease Aspirin-Sensitive Asthma With Nasal Polyps 收起 <<	Phase 2	Recruiting	February 2021	United States, Massachusetts ... 展开 >> Asthma Research Center, Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Meghan Le 617-732-8201 mle8@bwh.harvard.edu 收起 <<
NCT02682511	Scleroderma, Diffuse ... 展开 >> Scleroderma, Systemic Scleroderma, Limited Sclerosis, Progressive Systemic Skin Diseases Connective Tissue Diseases Pathologic Processes Autoimmune Diseases 收起 <<	Phase 2	Recruiting	February 2020	United States, California ... 展开 >> UCLA Recruiting Los Angeles, California, United States, 90095-1670 Contact: Nashla Barroso 310-825-9682 Principal Investigator: Suzanne Kafaja, MD United States, Florida New Life Medical Research Center, Inc. Recruiting Hialeah, Florida, United States, 33012 Contact: Barbara Diaz, BS 786-360-3750 diaz@newlifemedresearch.com Principal Investigator: Odalys P Frontela, MD United States, Maryland Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21224 Contact: Gwen Leatherman, RN, MS, CCRP 410-550-8582 Principal Investigator: Laura Hummer, MD United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Kaitlin Schalago 617-724-2792 Contact: Ana Fernandez 617-724-2792 Principal Investigator: Flavia Castelino, MD United States, New York Hospital for Special Surgery Recruiting New York, New York, United States, 10021 Contact: Alexandra Morquette 212-774-7194 Principal Investigator: Jessica Gordon, MD United States, South Carolina Medical University of South Carolina Recruiting Charleston, South Carolina, United States, 29403 Contact: Kelley Kajdasz 843-792-5290 Principal Investigator: Richard Silver, MD United States, Tennessee Vanderbilt University Medical Center Recruiting Nashville, Tennessee, United States, 37203 Contact: Rezzan Hekmat, MHS 615-875-8937 Principal Investigator: Evan Brittain, MD 收起 <<
NCT03028350	Asthma, Aspirin-Induced	Phase 2	Recruiting	December 2019	United States, California ... 展开 >> Scripps Clinic - Carmel Valley Recruiting San Diego, California, United States, 92130 Contact: Nancy Giovanetty 858-764-3023 Principal Investigator: Andrew White, MD Stanford University Medical Center Recruiting Stanford, California, United States, 94305 Contact: Aakanksha Rathor, MD 408-872-2257 Principal Investigator: Peter Hwang, MD United States, Florida The Research Center Recruiting Hialeah, Florida, United States, 33013 Contact: Laine Batista 305-603-8844 Contact: Damian Beltran-Garces (305) 603-8844 United States, Kansas Kansas City Allergy and Asthma Associates, PA Recruiting Overland Park, Kansas, United States, 66210 Contact: James B Sterner, MD 913-338-1610 Contact: Andrea Bennington, CCRC 913-338-1610 United States, New York Montefiore Medical Center Recruiting Bronx, New York, United States, 10461 Contact: Mydalyn Beronilla, MPH 929-263-3262 Principal Investigator: Elina Jerschow, MD United States, Ohio Clinical Research Trials , LLC Recruiting Canton, Ohio, United States, 44718 Contact: Nashat Gabrail, MD 330-492-3345 Contact: Hannah Crocker 330-492-3345 United States, Pennsylvania University of Pennsylvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: John V Bosso, MD Contact: Laurel Doghramji, BSN 215-615-1643 United States, Tennessee Vanderbilt University Medical Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Cindy Dorminy, MEd, LPN 615-936-8384 Principal Investigator: Rakesh Chandra, MD United States, Texas UT Southwestern Medical Center Recruiting Dallas, Texas, United States, 75390-9035 Contact: Mary Martin 214-648-3626 Principal Investigator: David Khan, MD United States, Virginia University of Virginia Medical Center Recruiting Charlottesville, Virginia, United States, 22908 Contact: B.J. Ferrebee Ghamandi, MHA 434-243-1558 Principal Investigator: Spencer Payne, MD 收起 <<
NCT01436500	-		Completed	-	-

确认信息

是否科研客户科研用途
是否

请登录您的专属账户

下列产品仅对科研客户提供相关信息。您需要登录/注册您的专属账户，或与客服人员直接联系确认您的产品用途，通过审核后，即可查看以下产品。

去登录

CAS号	143443-90-7
分子式	C₂₅H₃₂N₂O₅
分子量	440.532

别名	BMS-180291
运输	蓝冰

Ifetroban 99%

Ifetroban 纯度/质量文件

全球学术期刊中引用的产品

Ifetroban 生物活性

Ifetroban 临床研究

Ifetroban 实验方案

Ifetroban 技术信息

最近浏览的产品